Our clinical data showed that proinflammatory cytokine levels are elevated in the cerebrospinal fluid of patients with Col4a2 mutation-associated epilepsy, whereas the levels of these proinflammatory cytokines can be reduced after effective treatment. This evidence concerns the gene COL4A2 and epilepsy.